eli lilly glp-1 advantage decreasing Orforglipron: Lilly's New Oral Weight-loss Pill Companies are racing to improve

A.TonneijckL.HuangY.LiuM.SaremiA.Heerspinket al (2018)

Starting any medication is a big decision that requires a lot of thought and consideration

The medication is clearly doing something, just not producing weight loss anymore

We hope this approval supports increasing access to obesity care in the UK. The pills, which contain semaglutide, are now approved for adults who are obese (BMI of 30 or above) or overweight (BMI of 27-30) and have at least one weight-related health condition

Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits